STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Healthcare Pharmaceuticals
chemistry-2

Telomir Pharmaceuticals Unveils Groundbreaking Results with Telomir-1: A New Hope for Combating Oxidative Stress and Viral Infections

byLuca Blaumann
January 28, 2025
in Pharmaceuticals, Small-Cap
Reading Time: 3 mins read
Share on TwitterShare on LinkedIn

Innovative drug shows potential to address aging, chronic diseases, and avian influenza through oxidative stress reversal

Telomir Pharmaceuticals (TELO), a leader in age-reversal science, has announced transformative preclinical results for its groundbreaking compound, Telomir-1. The drug demonstrated the ability to fully reverse oxidative stress caused by copper-induced Reactive Oxygen Species (ROS) in human cell lines. This breakthrough positions Telomir-1 as a promising treatment for chronic diseases and viral infections, including avian influenza (bird flu).

Oxidative stress, driven by an imbalance between free radicals and antioxidants, is a key contributor to aging and diseases such as Alzheimer’s, cancer, cardiovascular conditions, and diabetes. It accelerates cellular damage, impairs immune responses, and exacerbates the progression of viral infections like bird flu. Telomir-1’s unique mechanism not only normalizes ROS levels but also protects cells from copper-induced toxicity, addressing the root causes of these conditions.

A Breakthrough in Cellular Protection
Telomir-1’s preclinical results highlighted three key achievements:

  • Oxidative Stress Reversal: The compound fully normalized ROS levels, reversing oxidative damage.
  • Cellular Protection: It safeguarded cells against copper toxicity, maintaining cellular integrity.
  • Low-Dose Efficacy: Telomir-1’s effects were observed at doses much lower than copper levels, demonstrating a novel regulatory mechanism beyond simple chelation.

Dr. Raphael Mayer, CEO of SmartAssays, emphasized, “These findings reveal Telomir-1’s exceptional therapeutic potential. Its ability to fully reverse oxidative stress marks a significant advance in addressing age-related diseases and viral infections.”

Potential Impact Across Major Diseases
Telomir-1’s unique approach could revolutionize treatments for several conditions:

  • Wilson’s Disease: By regulating copper metabolism, it could minimize side effects associated with current therapies.
  • Alzheimer’s Disease: Telomir-1 may slow neurodegeneration by reversing copper-related oxidative damage.
  • Age-Related Macular Degeneration (AMD): Its protective effects offer hope for preserving vision.
  • Cancer: The drug could enhance cancer treatments by mitigating ROS-driven DNA damage.
  • Cardiovascular Diseases: Telomir-1 may improve vascular health by reducing oxidative stress and inflammation.

Exploring Applications in Viral Infections
Telomir is also investigating Telomir-1’s potential to mitigate oxidative stress caused by viral infections, including avian influenza. With over 868 reported bird flu cases globally and a mortality rate of 50%, the need for effective therapies is critical. Telomir-1’s ability to protect cells and reverse oxidative damage could play a pivotal role in reducing disease severity and improving patient outcomes.

Telomir Pharmaceuticals is committed to advancing Telomir-1’s development, offering hope for millions worldwide.

You might like this article:Steel Veteran Alan Kestenbaum Eyes Leadership Role at U.S. Steel

Tags: GrowthMoversNewsStock MarketTELOTelomir Pharmaceuticals
Previous Post

Steel Veteran Alan Kestenbaum Eyes Leadership Role at U.S. Steel

Next Post

General Motors Reports $6 Billion Full-Year Net Income for 2024, Prepares for a Strong 2025

Related Posts

warehouse-2

Ideal Power Signs Strategic Distribution Deal With Kaimei Electronic Corp

byLuca Blaumann
June 10, 2025
0

Partnership with Kaimei Electronic to Promote B-TRAN Technology Across Key Power Electronics Sectors Ideal Power (IPWR), a leading innovator in...

trading-chart-2

Telomir Pharmaceuticals Reports Breakthrough Anti-Aging Results in Preclinical Werner Syndrome Model

byLuca Blaumann
June 5, 2025
0

Lead candidate Telomir-1 reverses aging markers, restores muscle mass, and boosts survival in genetic progeria model Telomir Pharmaceuticals (TELO), a...

opthalmology

Telomir Pharmaceuticals Reports Breakthrough in Oral Therapy for Vision Loss

byLiliana Vida
May 29, 2025
0

Telomir-1 reverses retinal degeneration and restores vision in advanced AMD zebrafish model Telomir Pharmaceuticals (TELO) announced a major preclinical breakthrough...

Next Post

General Motors Reports $6 Billion Full-Year Net Income for 2024, Prepares for a Strong 2025

Latest News

Lloyd Financial CEO & CIO Sees Golden Opportunity in Treasuries and Utilities Amid AI-Driven Deflation

Defense Stocks Rally as Middle East Tensions Escalate Following Israeli Airstrikes

Oracle Soars on Cloud Optimism and AI Momentum

Micron to Invest $30 Billion More in U.S. Semiconductor Expansion

Quantum Computing Stocks Soar After Nvidia CEO’s Bullish Outlook

Based on Your Interest

Mega-Cap

Revolutionizing the Barista Experience: Starbucks Rolls Out Generative AI Assistant

June 10, 2025
warehouse-2
Electrical Equipment

Ideal Power Signs Strategic Distribution Deal With Kaimei Electronic Corp

June 10, 2025
Brokerages

Circle Stock Soars 300% Post-IPO as Crypto Momentum Accelerates

June 9, 2025

Recommended

Large-Cap

IonQ Expands Quantum Ambitions with $1.08B Acquisition and Breakthrough Drug Simulation

June 9, 2025
Auto Manufacturers

Tesla Rebounds After $150B Sell-Off as Musk-Trump Feud Shows Signs of Easing

June 6, 2025
Mega-Cap

Broadcom Posts Record Q2 Revenue and Cash Flow on Soaring AI Demand

June 5, 2025
Mega-Cap

Lululemon Delivers Strong Q1 Growth, Driven by International Sales Surge

June 5, 2025
IT Services

AMD Acquires Brium to Bolster AI Software Capabilities

June 5, 2025
Stoxpo

Follow us on social media:

Highlights

  • Lloyd Financial CEO & CIO Sees Golden Opportunity in Treasuries and Utilities Amid AI-Driven Deflation
  • Defense Stocks Rally as Middle East Tensions Escalate Following Israeli Airstrikes
  • Oracle Soars on Cloud Optimism and AI Momentum
  • Micron to Invest $30 Billion More in U.S. Semiconductor Expansion
  • Quantum Computing Stocks Soar After Nvidia CEO’s Bullish Outlook

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

Lloyd Financial CEO & CIO Sees Golden Opportunity in Treasuries and Utilities Amid AI-Driven Deflation

June 13, 2025

Defense Stocks Rally as Middle East Tensions Escalate Following Israeli Airstrikes

June 13, 2025
code-3

Oracle Soars on Cloud Optimism and AI Momentum

June 12, 2025
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?